Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients

被引:127
作者
Brookhart, M. Alan [1 ,2 ]
Freburger, Janet K. [2 ]
Ellis, Alan R. [2 ]
Wang, Lily [2 ]
Winkelmayer, Wolfgang C. [3 ]
Kshirsagar, Abhijit V. [4 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA
[3] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA
[4] Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2013年 / 24卷 / 07期
基金
美国医疗保健研究与质量局;
关键词
CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; INTRAVENOUS IRON; ANEMIA MANAGEMENT; PARENTERAL IRON; ELEVATED FERRITIN; IV IRON; THERAPY; MORTALITY; ASSOCIATIONS;
D O I
10.1681/ASN.2012121164
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Intravenous iron may promote bacterial growth and impair host defense, but the risk of infection associated with iron supplementation is not well defined. We conducted a retrospective cohort study of hemodialysis patients to compare the safety of bolus dosing, which provides a large amount of iron over a short period of time on an as-needed basis, with maintenance dosing, which provides smaller amounts of iron on a regular schedule to maintain iron repletion. Using clinical data from 117,050 patients of a large US dialysis provider merged with data from Medicare's ESRD program, we estimated the effects of iron dosing patterns during repeated 1-month exposure periods on risks of mortality and infection-related hospitalizations during the subsequent 3 months. Of 776,203 exposure/follow-up pairs, 13% involved bolus dosing, 49% involved maintenance dosing, and 38% did not include exposure to iron. Multivariable additive risk models found that patients receiving bolus versus maintenance iron were at increased risk of infection-related hospitalization (risk difference [RD], 25 additional events/1000 patient-years; 95% confidence interval [CI], 16 to 33) during follow-up. Risks were largest among patients with a catheter (RD, 73 events/1000 patient-years; 95% CI, 48 to 99) and a recent infection (RD, 57 events/1000 patient-years; 95% CI, 19 to 99). We also observed an association between bolus dosing and infection-related mortality. Compared with no iron, maintenance dosing did not associate with increased risks for adverse outcomes. These results suggest that maintenance iron supplementation may result in fewer infections than bolus dosing, particularly among patients with a catheter.
引用
收藏
页码:1151 / 1158
页数:8
相关论文
共 35 条
[1]  
Besarab A, 1999, J AM SOC NEPHROL, V10, P2029
[2]   What are Common Misconceptions in Dialysis Patient Care? Anemia and Iron Management [J].
Besarab, Anatole .
SEMINARS IN DIALYSIS, 2011, 24 (05) :498-503
[3]   Iron supplementation to treat anemia in patients with chronic kidney disease [J].
Besarab, Anatole ;
Coyne, Daniel W. .
NATURE REVIEWS NEPHROLOGY, 2010, 6 (12) :699-710
[4]   Evolving Statistical Methods to Facilitate Evaluation of the Causal Association Between Erythropoiesis-Stimulating Agent Dose and Mortality in Nonexperimental Research: Strengths and Limitations [J].
Bradbury, Brian D. ;
Brookhart, M. Alan ;
Winkelmayer, Wolfgang C. ;
Critchlow, Cathy W. ;
Kilpatrick, Ryan D. ;
Joffe, Marshall M. ;
Feldman, Harold I. ;
Acquavella, John F. ;
Wang, Ouhong ;
Rothman, Kenneth J. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (03) :554-560
[5]  
Brewster UC, 2004, SEMIN DIALYSIS, V17, P57
[6]   Intravenous iron therapy in end-stage renal disease [J].
Brewster, Ursula C. .
SEMINARS IN DIALYSIS, 2006, 19 (04) :285-290
[7]   Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients [J].
Brookhart, M. Alan ;
Schneeweiss, Sebastian ;
Avorn, Jerry ;
Bradbury, Brian D. ;
Liu, Jun ;
Winkelmayer, Wolfgang C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (09) :857-864
[8]   Iron and infection: the heart of the matter [J].
Bullen, JJ ;
Rogers, HJ ;
Spalding, PB ;
Ward, CG .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2005, 43 (03) :325-330
[9]  
Cieri E, 1999, ANNA J, V26, P591
[10]  
Collins AJ, 2001, J AM SOC NEPHROL, V12, P2465, DOI 10.1681/ASN.V12112465